ArticleAnnals of medicine and surgery (2012)2025
Augmented reality for guiding biopsies in rare retroperitoneal fibrosis cases.
Article in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Retroperitoneal fibrosis (RPF) is a rare immune-mediated fibro-inflammatory disorder that often encases retroperitoneal structures, posing diagnostic and procedural challenges. Conventional image-guided biopsy techniques using CT or MRI may lead to missed lesions, sampling errors, and repeated procedures. Augmented reality (AR) platforms, such as Microsoft HoloLens-based systems, overlay 3D patient-specific anatomy in real time, enabling clinicians to visualize biopsy needle trajectories without dividing attention between monitors and the procedural field. Phantom studies have shown AR guidance can reduce soft tissue biopsy error from 1.52 to 0.75 cm, and lung lesion biopsy error from 1.12 to 0.62 cm. Despite promising accuracy gains, challenges remain in atypical RPF cases, including irregular lesion morphology, proximity to vital structures, and diagnostic ambiguity. Prospective multicenter studies are needed to confirm AR's clinical utility, assess cost-effectiveness, optimize training, and ensure practical and ethical integration into routine biopsy practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.